Naslov
Scleroderma and Lung

Autori
Peroš-Golubičić, Tatjana

Vrsta, podvrsta i kategorija rada
Poglavlja u knjigama, ostalo

Knjiga
Interstitial Lung Disease(Clinical Focus)

Urednik/ci
Sharma, Om

Izdavač
Jaypee Brothers

Grad
Delhi

Godina
2011

Raspon stranica
254-277

ISBN
9350252686

Ključne riječi
Scleroderma, Lung manifestations

Sažetak
Scleroderma is a chronic systemic disease of unknown cause, affecting around 15 persons in one million inhabitants in all parts of the world, but most frequently women between 40 and 60 years of age. Until recently scleroderma was considered to be a disease with gloomy prognosis and no cure. The general attitude has changed during last decades due to successful treatment of scleroderma renal crisis with ACE inhibitor drugs with consequent dramatic decrease of mortality. Today the pulmonary complications, interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading cause of death . Several studies showed that the disease modifying drug, cyclophosphamide, reduced the progression of scleroderma ILD in patients with early symptomatic disease with stabilization and also improved the extent of skin indurations. Pulmonary vasodilators have been shown to improve exercise tolerance and slow the rate of clinical deterioration in pulmonary arterial hypertension. Improved survival in scleroderma is associated also with better ascertainment of internal organ disease . All these data combined, contribute to the changing attitude towards scleroderma patients, with certain groups already having moderately better prognosis, and other emerging towards the same goal. The lung disease has the worst prognosis and governs the destiny of patients with scleroderma.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA